

# Analytical Methods

Accepted Manuscript




This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Rapid determination of orbifloxacin residue in milk by a optimized fluorescence polarization immunoassay (FPIA) based on a heterogeneous fluorescent tracer.



1                   **Development and Optimization of a Fluorescence**  
2                   **Polarization Immunoassay for Orbifloxacin in Milk**

3   Tiejun Mi,<sup>†a</sup> Xiao Liang,<sup>†a</sup> Long Ding,<sup>a</sup> Suxia Zhang,<sup>a</sup> Sergei A. Eremin,<sup>b</sup> Ross C.  
4   Beier,<sup>c</sup> Jianzhong Shen,<sup>a</sup> and Zhanhui Wang <sup>a\*</sup>

5   <sup>a</sup> *Department of Veterinary Pharmacology and Toxicology, College of Veterinary*  
6   *Medicine, China Agricultural University, Beijing 100193, People's Republic of China*

7   <sup>b</sup> *Department of Chemistry, M.V. Lomonosov Moscow State University, Moscow*  
8   *119991, Russia*

9   <sup>c</sup> *Food and Feed Safety Research Unit, Southern Plains Agricultural Research Center,*  
10 *Agricultural Research Service, U.S. Department of Agriculture, 2881 F&B Road,*  
11 *College Station, TX 77845-4988, USA*

12   <sup>†</sup>These authors contributed equally to this paper.

13   \*Author to whom correspondence should be addressed.

14   Tel: 8610 - 6273 3088

15   Fax: 8610 - 6273 3088

16   E-mail: wangzhanhui@cau.edu.cn

1  
2  
3  
4  
5 18 **Abstract** A novel monoclonal antibody for orbifloxacin (ORB) was produced for  
6  
7 19 the first time and used to develop a homogeneous fluorescence polarization  
8  
9  
10 20 immunoassay (FPIA) for ORB determination in milk. Three coating antigens and six  
11  
12 21 fluorescent tracers were prepared, and evaluated by ELISA and FPIA methods,  
13  
14  
15 22 respectively. Heterogeneous tracer, LOM-BDF, was selected to develop the FPIA,  
16  
17  
18 23 providing high sensitivity and stability. Moreover, a new optimization strategy for  
19  
20 24 tracer and Ab concentration was proposed by integrating  $Z'$  factor into checkerboard  
21  
22  
23 25 titration, and  $Z'$  factor  $> 0.8$  was considered as a prerequisite to ensure the robustness  
24  
25  
26 26 of quantitative FPIA. The optimized FPIA provided a detection limit of  $3.9 \text{ ng mL}^{-1}$   
27  
28 27 and  $\text{IC}_{50}$  of  $24.5 \text{ ng mL}^{-1}$  with an expected  $Z'$  factor of 0.81. Saturated  $(\text{NH}_4)_2\text{SO}_4$   
29  
30  
31 28 precipitation was applied for milk sample pre-treatment due to high tolerance to  
32  
33  
34 29 elevated-ionic strength in the FPIA. Mean recoveries of fortified milk were ranged  
35  
36 30 from 74.3 to 112 % at the adding levels of 10, 20 and  $40 \text{ ng mL}^{-1}$ . The results  
37  
38  
39 31 indicated that the developed FPIA was efficient and especially suitable for fast  
40  
41  
42 32 screening of ORB in milk.

43  
44  
45 33 **Keywords** Fluorescence polarization immunoassay; Assay optimization;  
46  
47  
48 34 Monoclonal antibody; Orbifloxacin; Milk  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1. Introduction

Quinolones (QNs) and the subset fluoroquinolones (FQs) represent a large group of synthetic antibiotics that are widely used for both the prevention and therapy of disease, not only in humans, but also in animal medicine. Some QNs including enrofloxacin (ENRO), danofloxacin (DANO), difloxacin (DIF), flumequine (FLU), marbofloxacin (MARB), orbifloxacin (ORB), oxolinic acid (OA) and sarafloxacin (SARA) are approved for veterinary practice in many countries.<sup>1,2</sup> However, residues of these drugs in food could pose potential threats to human health; moreover, these residues may contribute to the development of antibiotic resistant pathogenic bacteria.<sup>3,4</sup> With consideration of these potential hazards, in 2005 ENRO was withdrawn in the United States from use in poultry.<sup>5</sup> To minimize the risk of QNs exposure to humans *via* products from food-producing animals, maximum residue limits (MRLs) have been established for several QNs by a number of countries and organizations. Orbifloxacin, a third-generation fluoroquinolone developed exclusively for veterinary use, was approved in Japan for use in cattle and swine production for the treatment of gastrointestinal and respiratory infections, whereas in the United States it has been approved only for pets (dogs and cats).<sup>1,2,6</sup> MRL for ORB was set at 20 ng mL<sup>-1</sup> (g<sup>-1</sup>) in cattle and swine edible tissues and products, including milk.<sup>7</sup> It has been demonstrated that ORB transfers from the blood into the milk rapidly, and high-levels of ORB was observed in milk secretions.<sup>8</sup> Thus, it is necessary to develop reliable and accurate analytical methods for the determination of ORB residues in food animal products, especially milk.

1  
2  
3  
4 57 The basis of many methods used for analysis of QNs is dominated by liquid  
5  
6  
7 58 chromatography coupled with fluorescence detection or mass spectrometry, that  
8  
9  
10 59 indicate excellent sensitivity and accuracy.<sup>9, 10</sup> However, these instrumental  
11  
12 60 techniques are generally complicated, time-consuming, and expensive to use in  
13  
14  
15 61 routine screening programs. Immunoassay techniques like the enzyme-linked  
16  
17 62 immunosorbent assay (ELISA) may be an effective and economical alternative to  
18  
19  
20 63 instrumental methods. However, ELISA is a heterogeneous solid-phase method,  
21  
22  
23 64 which requires a long time (more than 2 h) for the immunoreactions to reach  
24  
25  
26 65 equilibrium and for multiple-washing steps to separate the free and antibody-bound  
27  
28  
29 66 analyte. Fluorescence polarization immunoassay (FPIA) is a competitive  
30  
31  
32 67 homogeneous assay in solution phase based on differences in fluorescence  
33  
34  
35 68 polarization (FP) of the fluorescent-labeled analyte in the antibody-bound and  
36  
37  
38 69 non-bound fractions. In a homogeneous solution phase immunoassay, the  
39  
40  
41 70 immunoreaction can reach equilibrium in minutes or even seconds, and no separation  
42  
43  
44 71 or washing steps are required. Although FPIA is prone to interference by matrix and  
45  
46  
47 72 antibody cross-reactivity, the advantage in detection speed makes it more suitable for  
48  
49  
50 73 determining a large number of samples than the ELISA.<sup>11</sup> Multiple-FPIAs have been  
51  
52  
53 74 developed for the determination of food contaminants, the majority of which are for  
54  
55  
56 75 analysis of pesticides<sup>12-15</sup> and for mycotoxins<sup>16-20</sup>. Also, some veterinary drugs in  
57  
58  
59 76 food residue, including sulfonamides<sup>21-26</sup>, maduramicin<sup>27</sup>, and chloramphenicol<sup>28</sup>  
60  
61  
62 77 have been analyzed by FPIA.

1  
2  
3  
4 78 In the current study, only two QNs, sparfloxacin (SPA) and lomefloxacin (LOM),  
5  
6  
7 79 which shared unique similarities with ORB in chemical structure, were cross-reactive  
8  
9  
10 80 with monoclonal antibody (MAb) against ORB, and selected to synthesize  
11  
12  
13 81 heterologous coating antigens for ELISA and fluorescent tracers for FPIA. Moreover,  
14  
15  
16 82 a new optimization strategy for tracer and Ab concentrations in FPIA was described  
17  
18  
19 83 based on  $Z'$  factor and checkerboard titration. To our knowledge, this is the first report  
20  
21  
22 84 for production of MAb against ORB, synthesis of fluorescent tracers and development  
23  
24  
25 85 of a FPIA for ORB determination.  
26  
27

## 28 87 **2. Materials and Methods**

### 29 30 31 88 *2.1 Chemicals and standards*

32  
33  
34 89 Bovine serum albumin (BSA), Ovalbumin (OVA), fluorescein isothiocyanate  
35  
36  
37 90 (FITC) isomer I, *N*-hydroxysuccinimide (NHS), *N,N'*-dicyclohexylcarbodiimide  
38  
39  
40 91 (DCC) and Freund's complete and incomplete adjuvants were obtained from  
41  
42  
43 92 Sigma-Aldrich (St. Louis, MO, USA). Polyethylene glycol (PEG 2000) was  
44  
45  
46 93 purchased from Merck-Schuchardt OHG (Darmstadt, Germany). Cell culture media  
47  
48  
49 94 (DMEM) was obtained from Huamei (Beijing, P.R. China). Fetal calf serum and  
50  
51  
52 95 supplements were obtained from GIBCO BRL (Carlsbad, CA). The analytical  
53  
54  
55 96 standards of orbifloxacin, sparfloxacin, lomefloxacin, enoxacin (ENO),  
56  
57  
58 97 marbofloxacin, ofloxacin (OFL), danofloxacin mesylate, oxolinic acid and nalidixic  
59  
60 98 acid (NAL) were obtained from Dr. Ehrenstorfer GmbH, (Ausburg, Germany).  
99 99 Ciprofloxacin hydrochloride (CIP), enrofloxacin, flumequine, norfloxacin (NOR),

1  
2  
3  
4 100 pefloxacin methanesulfonate (PEF), sarafloxacin, and difloxacin were purchased from  
5  
6  
7 101 the China Institute of Veterinary Drug Control (Beijing, P.R. China). Common  
8  
9  
10 102 solvents and salts were analytical reagent grade and supplied by Beijing Reagent  
11  
12 103 Corporation (Beijing, P.R. China).

14 104 Borate buffer (0.05 M, pH 8.0) with 0.1% sodium azide was used as the working  
15  
16  
17 105 buffer for all FPIA experiments. Individual stock standard solutions of the QNs (1 mg  
18  
19  
20 106 mL<sup>-1</sup>) were prepared by dissolving 10 mg of each QN standard in 1 mL of 0.03%  
21  
22  
23 107 NaOH and diluted to a final volume of 10 mL with methanol. Aqueous standard  
24  
25  
26 108 solutions of the analytes in the range of 0.1 to 1000 ng mL<sup>-1</sup> were prepared by dilution  
27  
28 109 of the stock solution with borate buffer.

## 30 110 2.2 apparatus

32  
33 111 Pre-coated silica gel 60G F<sub>254</sub> glass plates (plate size: 10 × 10 cm; layer  
34  
35  
36 112 thickness: 0.15 ~ 0.2 mm, particle size: 2 μm) for thin-layer chromatography (TLC)  
37  
38  
39 113 were purchased from Yantai XinDe Corporation (Shandong, P.R. China). Polystyrene  
40  
41  
42 114 microplates (96-well) for ELISA and black microplates (96-well) with a non-binding  
43  
44  
45 115 surface for FPIA were obtained from Corning Life Sciences (New York, NY, USA).  
46  
47  
48 116 A SpectraMax M5 microplate reader from Molecular Devices (Downingtown, PA,  
49  
50  
51 117 USA) was used to measure fluorescence polarization and optical density (OD) signal.  
52  
53  
54 118 High-performance liquid chromatography (HPLC) analysis were performed using a  
55  
56  
57 119 Waters 2695 Separations Module and a Waters 2475 Multi-Wavelength Fluorescence  
58  
59  
60 120 Detector equipped with a reverse-phase Symmetry C<sub>18</sub> 250 mm × 4.6 mm column  
121 (Waters, Milford, MA, USA).



1  
2  
3  
4 122 *2.3 Synthesis of protein and fluorescent conjugates*  
5

6  
7 123 The carboxylic group of ORB (20 mg, 50  $\mu\text{mol}$ ) was activated by gently stirring  
8  
9 124 overnight at room temperature in 1 mL of *N,N*-Dimethylformamide (DMF) containing  
10  
11 125 6 mg (60  $\mu\text{mol}$ ) of NHS and 12 mg (60  $\mu\text{mol}$ ) of DCC. The mixture was centrifuged  
12  
13 126 at  $1000 \times g$  for 10 mins to remove precipitated dicyclohexylurea. The clear  
14  
15 127 supernatant phase was collected and 900  $\mu\text{L}$  of the supernatant was added drop-wise  
16  
17 128 to 30 mg (0.5  $\mu\text{mol}$ ) BSA in 8 mL of sodium carbonate (0.01 M, pH 9.0). The  
18  
19 129 reaction was stirred overnight at  $4^\circ\text{C}$ , and then dialyzed against 1000 mL of PBS  
20  
21 130 (0.01 M, pH 7.4) for 3 days, which was changed twice a day. The immunogen,  
22  
23 131 ORB-BSA, was diluted to  $2 \text{ mg mL}^{-1}$  with PBS and divided into aliquots and stored at  
24  
25 132  $-20^\circ\text{C}$  until used. Three coating antigens (ORB-OVA, SPA-OVA and LOM-OVA)  
26  
27 133 were prepared in the same way.

28  
29 134 Three fluorescein derivatives, fluorescein thiocarbamyl ethylenediamine (EDF),  
30  
31 135 fluorescein thiocarbamyl butanediamine (BDF) and fluorescein thiocarbamyl  
32  
33 136 hexylenediamine (HDF) were synthesized from FITC as previously described.<sup>29</sup> ORB  
34  
35 137 (4 mg,  $10 \mu\text{mol}$ ) was activated with NHS and DCC as stated above and added to 4.8  
36  
37 138 mg ( $10 \mu\text{mol}$ ) of EDF in 0.5 mL DMF. After stirring for 12 h at RT, a small portion of  
38  
39 139 the reaction mixture was purified by TLC using methanol/AcOEt/ $\text{NH}_4\text{OH}$  (2:1:0.04,  
40  
41 140 v/v/v) as the eluent. The major yellow band at  $R_f$  0.5 was scraped from the plate and  
42  
43 141 extracted with methanol (0.2 mL). Other tracers ORB-BDF, ORB-HDF, LOM-EDF,  
44  
45 142 LOM-BDF and LOM-HDF were prepared by the same method (see Table 1). The  
46  
47 143 tracer concentration was calculated according to the absorbance at a wavelength of  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 144 492 nm<sup>28</sup>, and all the tracers were diluted with the borate buffer to get the routine  
5  
6  
7 145 working solution of 10nM, which the fluorescence intensity (FI) of tracers was about  
8  
9  
10 146 10 times that of buffer background (2 ~ 3 RFU).<sup>26</sup>

#### 11 147 *2.4 MAb production*

12  
13  
14  
15 148 The procedures used for MAb production were similar to those described in our  
16  
17 149 previous report.<sup>23</sup> Briefly, five 8-week old BALB/c mice were immunized with  
18  
19  
20 150 ORB-BSA at a dosage of 1 µg g<sup>-1</sup> body weight in an equal volume of Freund's  
21  
22  
23 151 complete adjuvant. Booster injections were then given 2, 4, and 6 weeks later with the  
24  
25  
26 152 same dosage of immunogen emulsified with an equal volume of Freund's incomplete  
27  
28  
29 153 adjuvant. Blood was collected from the caudal vein of each mouse and antisera titers  
30  
31  
32 154 were determined before fusion. The mouse exhibiting the highest-titer and best  
33  
34  
35 155 sensitivity was sacrificed after the last immunization and the spleen was removed for  
36  
37  
38 156 hybridoma production. After fusion, the cells were selected using the selection  
39  
40  
41 157 medium. The growing hybridoma cells were screened for antibody production by  
42  
43  
44 158 ELISA in the absence and presence of 100 ng mL<sup>-1</sup> ORB. The positive hybridomas  
45  
46  
47 159 were cloned by the limiting dilution method, and one stable clone was obtained.  
48  
49  
50 160 Ascites fluid of the positive hybridoma was collected and purified by (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>  
51  
52  
53 161 precipitation.

#### 54 162 *2.5 ELISA protocol*

55 163 The ELISA approach was described as follows: The ELISA plate was coated with  
56  
57  
58 164 coating antigen (100 µL per well) in coating buffer (0.05 M carbonate buffer, pH 9.6)  
59  
60 165 by incubation at 37 °C for 2 h. After washed with 300 µL per well of PBS (0.01 M,

1  
2  
3  
4 166 pH7.4) with 0.05% Tween20 for 4 times, the plate was blocked by incubation with  
5  
6  
7 167 300  $\mu\text{L}$  per well of blocking buffer (PBS with 1.0% casein) for 1h and followed by  
8  
9  
10 168 another washing step. Then 50  $\mu\text{L}$  per well of PBS in the absence or presence of  
11  
12 169 standard was added, followed by adding 50  $\mu\text{L}$  per well of diluted MAb. The plate  
13  
14  
15 170 was incubated for 30 mins at 37°C. After washing, 100  $\mu\text{L}$  of diluted goat-anti-mouse  
16  
17 171 IgG-HRP solution was added, and the plate was incubated for 30 mins at 37 °C again.  
18  
19  
20 172 Then, substrate solution (100  $\mu\text{L}$  per well) was added after washing, and the reaction  
21  
22  
23 173 was stopped by 50  $\mu\text{L}$  per well of 2 M  $\text{H}_2\text{SO}_4$  after incubation at 37°C for 15 mins.  
24  
25  
26 174 Then the OD value was determined in dual-wavelength mode (450 nm for test and  
27  
28 175 630 nm for reference). The concentrations of MAb and coating antigen were  
29  
30  
31 176 optimized by checkerboard titration according to  $B_0$  value of around 1.5 and  
32  
33 177 sensitivity

#### 36 178 *2.6 FPIA protocol*

39 179 The FPIA approach was described as follows: 50  $\mu\text{L}$  per well of tracer solution  
40  
41 180 was mixed with 50  $\mu\text{L}$  per well of borate buffer in the absence or presence of standard  
42  
43 181 in the microplate well. Subsequently, 50  $\mu\text{L}$  per well of diluted MAb was added, and  
44  
45 182 the mixtures were shaken for 10 s in the microplate reader. After a short incubation  
46  
47 183 period (2min) at room temperature, FP value was measured at  $\lambda_{\text{ex}} = 485 \text{ nm}$ ,  $\lambda_{\text{em}} = 530$   
48  
49 184 nm (emission cutoff = 515 nm, G factor = 1.0). And the blank control containing all  
50  
51  
52 185 assay elements except tracer was performed simultaneously for correcting polarization  
53  
54  
55 186 measurement by subtracting the background in assay buffer or sample matrix.  
56  
57  
58  
59  
60

1  
2  
3  
4 187 The antibody binding assay was performed by mixing tracer (10nM) with  
5  
6 188 two-fold serially diluted MAb over the range of 1/200 to 1/102400. Then antibody  
7  
8  
9 189 titers (the dilution resulting in 50% tracer binding) for different tracers were obtained  
10  
11  
12 190 according to the respective dilution curves. The optimal pair of fluorescent tracer and  
13  
14  
15 191 antibody concentrations were selected by checkerboard titration according to  
16  
17  
18 192 appropriate  $Z'$  factor<sup>30</sup> and sensitivity.

### 19 193 *2.7 Curve fitting and cross-reactivity determination*

20  
21  
22 194 The sigmoidal curve was used to fit both ELISA and FPIA data by OriginPro 7.0  
23  
24  
25 195 (OriginLab Corp., Northampton, MA, USA).  $IC_{50}$  was the standard concentration at  
26  
27  
28 196 50% of specific binding. The limit of detection (LOD) was defined as the standard  
29  
30  
31 197 concentration corresponding to the mean signal of 20 independent blank controls  
32  
33  
34 198 minus three times their standard deviation (SD). The limit of quantification (LOQ)  
35  
36  
37 199 was the standard concentration at  $IC_{80}$  and the dynamic range was defined as the  
38  
39  
40 200 standard concentration at the range of  $IC_{20} \sim IC_{80}$ . Cross-reactivity (CR) was  
41  
42  
43 201 calculated by both ELISA and FPIA methods according to the following equation:

$$44 \quad CR (\%) = (IC_{50} \text{ of ORB} / IC_{50} \text{ of tested QNs}) \times 100 \quad \text{Eq.1}$$

45  
46  
47 203 where  $IC_{50}$  values were obtained from calibration curves and CR was calculated using  
48  
49  
50 204  $IC_{50}$  values in nM unit.

### 51 205 *2.8 Effects of Physicochemical Conditions on Assay Performance*

52  
53  
54  
55 206 The effects of pH value, salt concentration, and organic solvent on assay  
56  
57  
58 207 performance were assessed by comparing  $\delta mP$  and  $IC_{50}$  parameters of the standard  
59  
60 208 curves under various conditions. The ORB standard, tracer and MAb were dissolved

1  
2  
3  
4 209 in buffers of different pH values, salt concentrations, and organic solvent  
5  
6  
7 210 concentrations, and were prepared as follows. The pH of a 50 mM borate buffer was  
8  
9  
10 211 about 9.4, and then the pH of the borate buffer was adjusted to different values (from  
11  
12 212 pH 5 to 10) with concentrated HCl or 6 M NaOH. Buffers of different ionic strength  
13  
14 213 (0 to 2.0 M) were prepared by adding solid NaCl to 50 mM borate buffer. Buffers  
15  
16 214 with different organic solvents were comprised of 50 mM borate buffer containing  
17  
18 215 methanol or acetonitrile in different proportions (0 to 20%).  
19  
20  
21  
22

### 23 216 *2.9 Sample preparation*

24  
25 217 Negative control milk (4 mL) was added into 10 mL polypropylene centrifuge  
26  
27 218 tubes and fortified with the appropriate ORB standard solution. After mixing with a  
28  
29 219 vortex mixer, the samples were allowed to stand for 30 mins in the dark at RT. An  
30  
31 220 equal volume of saturated  $(\text{NH}_4)_2\text{SO}_4$  solution was added to deproteinize the samples  
32  
33 221 followed by mixing in a vortex mixer, and then sonicating for 5 mins. The mixtures  
34  
35 222 were centrifuged at  $7400 \times g$  at  $4^\circ\text{C}$  for 10 mins. Some of the clear supernatant  
36  
37 223 (500  $\mu\text{L}$ ) was filtered through a 0.45  $\mu\text{m}$  filter and 50  $\mu\text{L}$  of the filtrate was analyzed  
38  
39 224 by FPIA. Additionally, 4 mL of supernatant was collected and the pH adjusted to 6.0  
40  
41 225 by the addition of HCl, followed by extracting with 4 mL of dichloromethane  
42  
43 226 ( $\text{CH}_2\text{Cl}_2$ ). The whole lower organic layer (around 4 mL) was transferred into an  
44  
45 227 eppendorf tube and evaporated under a stream of nitrogen gas at  $40^\circ\text{C}$ . The residue  
46  
47 228 was re-dissolved in 1.0 mL of the mobile phase and filtered through a 0.45  $\mu\text{m}$  filter,  
48  
49 229 50  $\mu\text{L}$  of the filtrate was subjected to HPLC analysis. HPLC method was modified  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60 230 based on the previous study.<sup>8</sup> The mobile phase consisted of a mixture of acetonitrile

1  
2  
3  
4 231 and 0.5% trifluoroacetic acid solution (20:80, v/v). The HPLC system was operated  
5  
6  
7 232 isocratically at a flow rate of 0.8 mL min<sup>-1</sup> and fluorescence detection was conducted  
8  
9  
10 233 at an excitation wavelength of 280 nm and an emission wavelength of 450 nm.  
11

12 234

### 15 235 **3. Results and discussion**

#### 17 236 *3.1 Characterization and selection of tracers*

19  
20 237 In this study, three coating antigens (ORB-OVA, SPA-OVA and LOM-OVA)  
21  
22  
23 238 were prepared with respective cross-reactants (ORB, SPA and LOM), and evaluated  
24  
25  
26 239 in ELISA method. As observed in Fig. 1, the heterogenous coating antigen  
27  
28  
29 240 LOM-OVA exhibited the highest sensitivity in ELISA method. Then, LOM was  
30  
31  
32 241 selected to prepare heterogeneous fluorescent tracers to investigate the effect of tracer  
33  
34  
35 242 structure on the analytical characteristics of the FPIA. Three synthesized  
36  
37  
38 243 heterogeneous tracers which were different in the bridge length between LOM and  
39  
40  
41 244 fluorescein (two carbons length for LOM-EDF, four carbons length for LOM-BDF  
42  
43  
44 245 and six carbons length for LOM-HDF) were expected to improve assay sensitivity.  
45  
46  
47 246 And other three similar tracers, ORB-EDF, ORB-BDF and ORB-HDF were prepared  
48  
49  
50 247 as the homogeneous controls.

51  
52 248 Six tracers were firstly characterized by the antibody binding assay. As the results  
53  
54  
55 249 shown in Fig. 2, antibody titers for LOM-EDF, LOM-BDF, LOM-HDF, ORB-EDF,  
56  
57  
58 250 ORB-BDF and ORB-HDF were 1/1600, 1/2400, 1/4000, 1/3000, 1/7000 and 1/8000,  
59  
60 251 respectively. But two of these tracers (LOM-EDF, ORB-EDF) did not present the  
252 adequate increase in FP signal ( $\delta mp < 100$ ) after adding saturating amounts of

1  
2  
3  
4 253 antibody. Other four tracers giving satisfactory binding ( $\delta mp > 180$ ) were subjected to  
5  
6  
7 254 a further identification by ESI-MS in positive ion mode, which indicated the  $m/z$  of  
8  
9  
10 255 810.6 for LOM-BDF, 839.4 for LOM-HDF, 850.4 for ORB-BDF, 875.4 for  
11  
12 256 ORB-HDF. Optimal tracer was selected according to assay sensitivity and stability  
13  
14  
15 257 that displayed in Fig. 3. The highest-sensitivity (lowest  $B/B_0$ ) was obtained when  
16  
17  
18 258 using the heterogeneous tracer LOM-BDF with shorter linker (four carbons length).  
19  
20 259 Generally, the antibody affinity for the hapten conjugate is higher than the analyte  
21  
22 260 itself due to the homology of the hapten used in the immunogen and tracer.<sup>31</sup> In order  
23  
24  
25 261 to achieve the high sensitivity, the antibody affinity for the tracer should be of the  
26  
27  
28 262 same order of magnitude as for the analyte.<sup>32</sup> So, the tracers with structurally  
29  
30  
31 263 heterogeneous hapten or linker between hapten and fluorescein were considered to  
32  
33  
34 264 change the affinity with Ab. In agreement with previous reports<sup>23,31</sup>, the  
35  
36  
37 265 heterogeneous tracer LOM-BDF with shorter linker provided lower-relative affinity  
38  
39  
40 266 with antibody, resulting in higher-sensitivity in our work.

41  
42 267 Moreover, FP signal was much more stable using the heterogeneous tracers  
43  
44 268 during the incubation time over 60 mins compared with homogeneous tracers (Fig. 3).  
45  
46  
47 269 Only a short incubation time (1 min) was required to reach interaction equilibrium,  
48  
49  
50 270 which proved to be more likely to develop a real “mix and read” assay. Thus, total  
51  
52  
53 271 time required for one 96-well microplate was about 15 mins for FPIA compared with  
54  
55  
56 272 more than 2 h for a conventional ELISA. So, LOM-BDF was selected as the optimal  
57  
58  
59 273 tracer in the following studies.

60 274 *3.2 Z factor in FPIA*

1  
2  
3  
4 275 The Z factor (Eq.2) is a widely used statistical parameter to judge assay quality  
5  
6  
7 276 in high-throughput screening (HTS) assays, which indicates the ability to distinguish  
8  
9  
10 277 signals between sample and control.

$$11 \quad 278 \quad Z = 1 - (3\sigma_s + 3\sigma_c)/|\mu_s - \mu_c| \quad \text{Eq.2}$$

12  
13  
14  
15 279 Where  $\mu_s$  and  $\mu_c$  represent the average signal of the sample and the control,  
16  
17  
18 280 respectively. And  $\sigma_s$  and  $\sigma_c$  are the respective SDs of these values.  $Z \geq 0.5$  represents  
19  
20 281 good separation of the distributions and indicates an excellent assay;  $0 < Z < 0.5$  means  
21  
22 282 moderate separation of the distributions and indicates a doable assay;  $Z < 0$  is a sign of  
23  
24  
25 283 poor quality. Similarly, this factor can also serve as the parameter for the quality of  
26  
27  
28 284 the assay itself, which defined as Z' factor:

$$29 \quad 30 \quad 31 \quad 32 \quad 33 \quad 34 \quad 35 \quad 36 \quad 37 \quad 38 \quad 39 \quad 40 \quad 41 \quad 42 \quad 43 \quad 44 \quad 45 \quad 46 \quad 47 \quad 48 \quad 49 \quad 50 \quad 51 \quad 52 \quad 53 \quad 54 \quad 55 \quad 56 \quad 57 \quad 58 \quad 59 \quad 60$$

$$285 \quad Z' = 1 - (3\sigma_{c+} + 3\sigma_{c-})/|\mu_{c+} - \mu_{c-}| \quad \text{Eq.3}$$

286 Where  $\mu_{c+}$  and  $\mu_{c-}$  represent the average signal of the positive and negative control,  
287 respectively. And  $\sigma_{c+}$  and  $\sigma_{c-}$  are the respective SD of these values.<sup>30</sup>

288 In order to apply Z factor in competitive FPIA for quantitative determination,  
289 these two factors were similarly defined as:

$$290 \quad Z = 1 - 3 \times (SD_{\max} + SD_x)/(mP_{\max} - mP_x) \quad \text{Eq.4}$$

$$291 \quad Z' = 1 - 3 \times (SD_{\max} + SD_{\min})/(mP_{\max} - mP_{\min}) \quad \text{Eq.5}$$

292 Where  $mP_{\max}$  and  $mP_{\min}$  are the observed mean FP signal for bound and free  
293 fluorescent tracer. Generally,  $mP_{\max}$  and  $mP_{\min}$  represent maximum (no inhibition) and  
294 minimum (complete inhibition) signal in standard curve;  $mP_{\max} - mP_{\min}$ , represents  
295 the assay window ( $\delta mP$ );  $mP_x$  is the observed mean FP value in the presence of



1  
2  
3  
4 296 analyte at some concentration;  $SD_{\max}$ ,  $SD_{\min}$  and  $SD_x$  are the respective SDs of these  
5  
6  
7 297 values.

8  
9  
10 298 Typically, a  $Z'$  factor  $\geq 0.5$  indicates a reliable assay in HTS. However, that may  
11  
12 299 be not a suitable threshold value for quantitative determination in our opinion. If  $Z'$   
13  
14 300 factor = 0.5,  $Z_{50} = 0$  ( $Z$  at  $IC_{50}$ ), that inevitably resulted in poor quality ( $Z < 0$ ) for the  
15  
16  
17 301 concentration less than  $IC_{50}$ . On account of defining  $IC_{80}$  as LOQ, it was essential to  
18  
19  
20 302 keep  $Z_{80} > 0$  ( $Z$  at  $IC_{80}$ ) in quantitative FPIA. As displayed in Fig. 4,  $mP_{\max} - mP_{80} >$   
21  
22  
23 303  $6SD$  and  $\delta mP > 30SD$  were achieved in the case of almost constant variance in FP  
24  
25  
26 304 value for the fixed tracer concentration (shown in Fig. 5). Consequently,  $Z' > 0.8$  was  
27  
28  
29 305 obtained and considered as a prerequisite to ensure the robustness of quantitative  
30  
31  
32 306 FPIA.

### 33 307 *3.3 Tracer and antibody concentration*

34  
35  
36 308 It is known that the tracer signal sets the sensitivity, low tracer concentration will  
37  
38  
39 309 result in the high sensitivity. In previous reports, tracer working solution was  
40  
41  
42 310 empirically set to its concentration exhibited about 10 times more FI signal than the  
43  
44  
45 311 buffer background.<sup>26,32</sup> However, the precision of FP signal (SD), rather than the FP  
46  
47  
48 312 signal itself, is related to the tracer concentration, low tracer concentration also results  
49  
50  
51 313 in low precision in FP signal.<sup>33</sup> As the results shown in Fig. 5, almost constant SD of  
52  
53  
54 314 FP value ( $SD_{\max} \approx SD_{\min} \approx SD$ ) was observed for the fixed tracer concentration, and  
55  
56  
57 315 precision decreased for the tracer concentration less than 10nM. It has been proved  
58  
59  
60 316 that the dilution of antibody corresponding to 50% tracer binding would provide best  
317 sensitivity.<sup>23</sup> However, the FP assay window ( $\delta mP$ ) is very narrow and dependent on

1  
2  
3  
4 318 the concentration of Ab, and low Ab concentration will not provide a good assay  
5  
6  
7 319 window for measurement.<sup>34</sup>  
8

9  
10 320 Therefore, it is necessary to establish a method for optimization of their  
11  
12 321 concentrations simultaneously. One of the most effective methods was checkerboard  
13  
14  
15 322 titration, which has been widely applied in ELISA optimization. Moreover,  $Z'$  factor  
16  
17 323 was integrated into checkerboard titration, due to it incorporating the precision of FP  
18  
19  
20 324 signal and the assay window. As the results shown in Table. 2, 20 nM of LOM-BDF  
21  
22  
23 325 and 1/1600 of Ab dilution were selected as the optimal couple for the tracer and Ab  
24  
25  
26 326 concentrations on the basis of  $Z'$  factor  $> 0.8$  and higher sensitivity (lower  $B/B_0$ ). 20  
27  
28 327 nM of LOM-BDF giving FI of  $\sim 50$  RFU was approximately 20 times that of the  
29  
30  
31 328 background signal for borate buffer, and assay window was about 130 mP obtained at  
32  
33  
34 329 1/1600 of Ab dilution, which was corresponding to 60% tracer binding. The optimal  
35  
36 330 standard curve was shown in Fig. 4 with a  $IC_{50}$  of  $24.5 \text{ ng mL}^{-1}$ , LOD of  $3.7 \text{ ng mL}^{-1}$ ,  
37  
38 331 dynamic range of  $7.3\text{--}90.7 \text{ ng mL}^{-1}$ ,  $R^2$  of 0.997 and expected precision ( $Z' = 0.81$ ).  
39  
40

#### 41 332 *3.4 Cross-reactivity determination*

42  
43  
44 333 The specificity of the ORB MAb was evaluated by determining the cross-reactivity  
45  
46  
47 334 with 15 other QNs (SPA, LOM, ENO, MARB, OFL, DANO, OA, NAL, ENRO, CIP,  
48  
49  
50 335 NOR, FLU, PEF, SARA and DIF) in both the ELISA and FPIA (Table 3). The MAb  
51  
52 336 showed medium and less cross-reactivity with SPA and LOM, respectively, and  
53  
54  
55 337 showed negligible cross-reactivity with the other QNs. Based on the cross-reactivity  
56  
57  
58 338 results, some substituents of LOM, ORB and SPA may play important roles in the  
59  
60 339 antibody recognition; when the  $CH_3$ -group is present at the  $R_3$  or  $R_5$  position of the

1  
2  
3  
4 340 piperazine ring, and when the fluorine substituent is at the C<sub>8</sub> position of the  
5  
6  
7 341 quinolone nucleus, which are nonexistent structural features in other QNs (see Table  
8  
9  
10 342 1).

### 11 343 *3.5 Effects of Physicochemical Conditions on Assay Performance*

#### 12 344 *3.5.1 pH effects*

13  
14  
15  
16  
17 345 The relationship of the IC<sub>50</sub> and  $\delta$ mP as a function of pH was shown in Fig. 6(a).  
18  
19  
20 346 The lowest IC<sub>50</sub> and highest  $\delta$ mP were obtained at pH 8; whereas,  $\delta$ mP was  
21  
22  
23 347 significantly reduced and the IC<sub>50</sub> was lower at pH 9 and 10. The results demonstrate  
24  
25  
26 348 that the assay performed optimally at pH 8, and did not function well at higher or  
27  
28 349 lower pH values.

#### 29 350 *3.5.2. Ionic strength*

30  
31  
32  
33 351 The assay was tested in working buffer with salt concentrations ranging between  
34  
35  
36 352 0 and 1.5 M, and the results are presented in Fig. 6(b). No negative effect on the IC<sub>50</sub>  
37  
38  
39 353 or  $\delta$ mP was observed at salt concentrations ranging from 0 to 1.0 M. A 30% increase  
40  
41  
42 354 in the IC<sub>50</sub> occurred as a result of the 1.5 M salt concentration, and  $\delta$ mP  
43  
44  
45 355 simultaneously increased by 10%. Therefore, elevated-ionic strength did not  
46  
47 356 remarkably affect the FPIA.

#### 48 357 *3.5.3 Organic solvent*

49  
50  
51  
52 358 The effects of methanol and acetonitrile were studied because these solvents are  
53  
54  
55 359 water-miscible and commonly used in sample extraction procedures. However, only  
56  
57  
58 360 10% methanol or 2.5 % acetonitrile could be tolerated in current assay (Data not  
59  
60 361 shown).

### 362 3.6 Analysis of spiked milk

363 A FPIA method was developed to determine ORB in milk. Milk is a very  
364 complex matrix consisting of different components (fats, proteins, various sugars,  
365 etc.), which can strongly interfere with the analytical determination of residues.<sup>28</sup>  
366 FPIA is susceptible to some of these components; therefore, milk protein removal is  
367 required. Since elevated-ionic strength almost does not affect the performance of our  
368 FPIA, a saturated solution of (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> was used for protein precipitation in the  
369 recovery study, which has proved efficient for removing protein from milk.<sup>28</sup> In order  
370 to confirm the recovery results, the samples were simultaneously analyzed by HPLC  
371 after a liquid–liquid extraction (LLE) clean-up step. The mean recoveries were 74.3 to  
372 112 % with coefficient of variation (CV) ranging from 7.4 to 26.8 % at the adding  
373 levels of 0.5 ~ 2 MRLs (shown in Table 4), and improved recovery and coefficients of  
374 variation were observed by HPLC determination following the clean-up step. FPIA  
375 standard curves performed in both borate buffer and milk matrix were displayed in  
376 Fig.7, which suggests that the (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> precipitation step did not completely  
377 eliminate the matrix interference from milk; however, it was not only a sufficient  
378 pretreatment for screening assay, but a safe and environmental-friendly technology.  
379 Twenty four milk samples collected from the local markets were determined by these  
380 two methods, no positive results were found in these samples.

## 381 4. Conclusions

382 A rapid, simple, and sensitive FPIA for orbifloxacin determination in milk was  
383 developed for the first time. LOM-BDF with 4 carbon linkers was selected as optimal

1  
2  
3  
4 384 fluorescent tracer due to its high sensitivity and short incubation time (1min). Total  
5  
6  
7 385 time required for measuring one 96-well microplate was about 15 mins for FPIA in  
8  
9  
10 386 comparison with more than 2 h for a conventional ELISA.  $Z'$  factor $>0.8$  was  
11  
12 387 considered as the prerequisite to ensure the robustness of quantitative FPIA, and the  
13  
14  
15 388 optimized FPIA showed satisfactory results for ORB analysis in milk using a simple  
16  
17  
18 389 and safe sample pre-treatment. The optimization strategy for tracer and Ab  
19  
20  
21 390 concentrations described in the present study could be beneficial in the development  
22  
23 391 of FPIA for quantitative determination.

## 24 25 26 392 **Acknowledgements**

27  
28  
29 393 This work is supported by the grants from Trans-Century Training Programme  
30  
31  
32 394 Foundation for the Talents by the Ministry of Education (NCET-12-0529), National  
33  
34  
35 395 Natural Science Foundation of China (No.31372475), CAU Fundamental Research  
36  
37  
38 396 Funds (2012QJ111), Beijing Excellent Doctoral Dissertation Fund (YB20081001902)  
39  
40  
41 397 and Sino-Russian International Scientific and Technological Cooperation  
42  
43 398 (2011DFR30470).

399 **References**

- 400 1. J. E. Riviere and M. G. Papich, *Veterinary pharmacology and therapeutics consulting editor*  
401 *H. Richard Adams*, 9th ed. edn., Wiley-Blackwell, Ames (Iowa), 2009.
- 402 2. V. Andreu, C. Blasco and Y. Picó, *TrAC - Trends in Analytical Chemistry*, 2007, **26**, 534-556.
- 403 3. K. E. Smith, J. M. Besser, C. W. Hedberg, F. T. Leano, J. B. Bender, J. H. Wicklund, B. P.  
404 Johnson, K. A. Moore and M. T. Osterholm, *N Engl J Med*, 1999, **340**, 1525-1532.
- 405 4. A. Fàbrega, J. Sánchez-Céspedes, S. Soto and J. Vila, *International Journal of Antimicrobial*  
406 *Agents*, 2008, **31**, 307-315.
- 407 5. J. M. Nelson, T. M. Chiller, J. H. Powers and F. J. Angulo, *Clin Infect Dis*, 2007, **44**, 977-980.
- 408 6. S. Nakamura, *Drugs*, 1995, **49**, 152-158.
- 409 7. The maximum residue limits of substances used as ingredients of agricultural chemicals in  
410 foods (Provisional MRLs List).  
411 <http://www.mhlw.go.jp/english/topics/foodsafety/positivelist060228/dl/index-1b.pdf>.
- 412 8. P. Marín, E. Escudero, E. Fernández-Varón and C. M. Cárceles, *Journal of Dairy Science*,  
413 2007, **90**, 4219-4225.
- 414 9. N. Dorival - García, A. Zafra - Gómez, S. Cantarero, A. Navalón and J. L. Vílchez,  
415 *Microchemical Journal*, 2013, **106**, 323-333.
- 416 10. S. Zhao, H. Jiang, X. Li, T. Mi, C. Li and J. Shen, *Journal of Agricultural and Food*  
417 *Chemistry*, 2007, **55**, 3829-3834.
- 418 11. D. S. Smith and S. A. Eremin, *Analytical and Bioanalytical Chemistry*, 2008, **391**, 1499-1507.
- 419 12. M. A. Deryabina, Y. N. Yakovleva, V. A. Popova and S. A. Eremin, *Journal of Analytical*  
420 *Chemistry*, 2005, **60**, 80-85.
- 421 13. S. A. Eremin, I. A. Ryabova, J. N. Yakovleva, E. V. Yazynina, A. V. Zherdev and B. B.  
422 Dzantiev, *Analytica Chimica Acta*, 2002, **468**, 229-236.
- 423 14. Z. L. Xu, Q. Wang, H. T. Lei, S. A. Eremin, Y. D. Shen, H. Wang, R. C. Beier, J. Y. Yang, K.  
424 A. Maksimova and Y. M. Sun, *Anal Chim Acta*, 2011, **708**, 123-129.
- 425 15. H. Lei, G. Xue, C. Yu, S. A. Haughey, S. A. Eremin, Y. Sun, Z. Wang, Z. Xu, H. Wang, Y.  
426 Shen and Q. Wu, *Analytical Methods*, 2011, **3**, 2334-2340.
- 427 16. E. H. Choi, D. M. Kim, S.-W. Choi, S. A. Eremin and H. S. Chun, *International Journal of*  
428 *Food Science & Technology*, 2011, **46**, 2173-2181.
- 429 17. F. Zezza, F. Longobardi, M. Pascale, S. A. Eremin and A. Visconti, *Analytical and*  
430 *Bioanalytical Chemistry*, 2009, **395**, 1317-1323.
- 431 18. C. M. Maragos and R. D. Plattner, *J Agric Food Chem*, 2002, **50**, 1827-1832.
- 432 19. C. M. Maragos, M. E. Jolley, R. D. Plattner and M. S. Nasir, *J Agric Food Chem*, 2001, **49**,  
433 596-602.

- 1  
2  
3  
4 434 20. C. M. Maragos, M. E. Jolley and M. S. Nasir, *Food Addit Contam*, 2002, **19**, 400-407.  
5  
6 435 21. Z. Wang, S. Zhang, S. Ding, S. A. Eremin and J. Shen, *Food Additives and Contaminants -*  
7 436 *Part A Chemistry, Analysis, Control, Exposure and Risk Assessment*, 2008, **25**, 574-582.  
8  
9 437 22. S. Zhang, Z. Wang, I. S. Nesterenko, S. A. Eremin and J. Shen, *International Journal of Food*  
10 438 *Science and Technology*, 2007, **42**, 36-44.  
11  
12 439 23. Z. Wang, S. Zhang, I. S. Nesterenko, S. A. Eremin and J. Shen, *Journal of Agricultural and*  
13 440 *Food Chemistry*, 2007, **55**, 6871-6878.  
14  
15 441 24. S. A. Eremin, N. R. Murtazina, D. N. Ermolenko, A. V. Zherdev, A. A. Mart'ianov, E. V.  
16 442 Yazynina, I. V. Michura, A. A. Formanovsky and B. B. Dzantiev, *Analytical Letters*, 2005,  
17 443 **38**, 951-969.  
18  
19 444 25. N. R. Murtazina, S. A. Eremin, O. V. Mozoleva, S. J. Everest, A. Jim Brown and R. Jackman,  
20 445 *International Journal of Food Science & Technology*, 2004, **39**, 879-889.  
21  
22 446 26. S. A. Eremin, J. Landon, D. S. Smith and R. Jackman, *Analyst*, 1994, **119**, 2723-2726.  
23  
24 447 27. Z. Wang, S. Zhang, N. R. Murtazina, S. A. Eremin and J. Shen, *International Journal of Food*  
25 448 *Science and Technology*, 2008, **43**, 114-122.  
26  
27 449 28. N. V. Gasilova and S. A. Eremin, *Journal of Analytical Chemistry*, 2010, **65**, 255-259.  
28  
29 450 29. C. Nistor, A. Oubiña, M. P. Marco, D. Barceló and J. Emnéus, *Analytica Chimica Acta*, 2001,  
30 451 **426**, 185-195.  
31  
32 452 30. J. H. Zhang, T. D. Y. Chung and K. R. Oldenburg, *Journal of Biomolecular Screening*, 1999,  
33 453 **4**, 67-73.  
34  
35 454 31. A. I. Krasnova, S. A. Eremin, M. Natangelo, S. Tavazzi and E. Benfenati, *Analytical Letters*,  
36 455 2001, **34**, 2285-2301.  
37  
38 456 32. P. Onnerfjord, S. Eremin, J. Emneus and G. Marko-Varga, *J Immunol Methods*, 1998, **213**,  
39 457 31-39.  
40  
41 458 33. N. Ehrlich, A. L. Christensen and D. Stamou, *Anal Chem*, 2011, **83**, 8169-8176.  
42  
43 459 34. N. J. Moerke, in *Current Protocols in Chemical Biology*, John Wiley & Sons, Inc., 2009.  
44  
45 460  
46  
47  
48 461  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 462 **Figure Captions**  
5  
6

7 463 Fig. 1. The normalized ELISA calibration curves using three coating antigens:  
8  
9  
10 464 LOM-OVA ( $IC_{50} = 5.53 \text{ ng mL}^{-1}$ ), SPA-OVA ( $IC_{50} = 8.13 \text{ ng mL}^{-1}$ ) and ORB-OVA  
11  
12 465 ( $IC_{50} = 14.8 \text{ ng mL}^{-1}$ ). Each point of the curve represents the mean Absorbance  $\pm$  SD  
13  
14  
15 466 ( $n=3$ ).  
16  
17

18 467 Fig. 2. Antibody binding curves for the anti-ORB MAb with six tracers: LOM-EDF,  
19  
20 468 LOM-BDF, LOM-HDF, ORB-EDF, ORB-BDF and ORB-HDF with antibody titers of  
21  
22 469 1/1600, 1/2400, 1/4000, 1/3000, 1/7000 and 1/8000, respectively.  
23  
24  
25

26 470 Fig. 3. Screening the optimal tracer by comparison of four tracers in sensitivity and  
27  
28 471 stability by incubating the assay at room temperature over 60mins. Each point  
29  
30  
31 472 represents the mean of three replicates ( $n=3$ ). The data was measured under 10 nM of  
32  
33  
34 473 tracers and respective antibody titers.  $\delta mP = mP_{\max} - mP_{\min}$ , represented the assay  
35  
36 474 window.  $B/B_0$  was calculated at the ORB concentration of  $20 \text{ ng mL}^{-1}$ .  
37  
38

39 475 Fig. 4.  $Z' > 0.8$  was proposed as the prerequisite to ensure the robustness of FPIA  
40  
41  
42 476 according to  $Z_{80} > 0$ .  $Z_{80}$  was the Z factor obtained at  $IC_{80}$ ;  $mP_{80}$  was the mean FP  
43  
44 477 value at  $IC_{80}$  (LOQ).  
45  
46


47 478 Fig. 5. SD of the FP signal relatively depends on the tracer concentration  
48  
49 479 (Fluorescence intensity).  $mP_{\max}$  was the mean FP measured by mixing LOM-BDF  
50  
51 480 with saturating amounts of antibody (1/100) ;  $mP_{\min}$  was the mean FP for free tracer  
52  
53 481 (LOM-BDF),  $SD_{\max}$  and  $SD_{\min}$  were the respective SDs. Each point represents the  
54  
55  
56 482 mean of eight replicates ( $n=8$ ).  
57  
58  
59  
60



1  
2  
3  
4 483 Fig. 6. Effect of a) pH and b) assay buffer salt concentration on the analytical  
5  
6  
7 484 characteristics of the ORB competitive standard curve. Each point represents the  
8  
9  
10 485 mean of three replicates.

11  
12 486 Fig. 7. The normalized standard curves for the FPIA determination of ORB in borate  
13  
14  
15 487 buffer ( $IC_{50} = 24.5 \text{ ng mL}^{-1}$ ) and milk matrix ( $IC_{50} = 21.7 \text{ ng mL}^{-1}$ ). Each point of the  
16  
17  
18 488 curve represents the mean  $FP \pm SD$  ( $n=3$ ).

489



490

491

Fig.1.




Fig.2.

492

493






Fig.3.



496

497

Fig.4.



498

499

500

Fig.5.





Fig.6.

501

502

503



504


505

506

Fig.7.



507 Table 1. Chemical Structures of Fluoroquinolone Drugs, Hapten-Protein Conjugates (Immunogen  
 508 and coating antigens), and Fluorescent tracers.



509

Compound	Substituents					
	R <sub>3'</sub>	R <sub>5'</sub>	R <sub>1</sub>	R <sub>5</sub>	R <sub>8</sub>	R <sub>3</sub>
FQs						
ORB	CH <sub>3</sub>	CH <sub>3</sub>	△	F	F	COOH
SPA	CH <sub>3</sub>	CH <sub>3</sub>	△	NH <sub>2</sub>	F	COOH
LOM	H	CH <sub>3</sub>	C <sub>2</sub> H <sub>5</sub>	H	F	COOH
Immunogen						
ORB-BSA	CH <sub>3</sub>	CH <sub>3</sub>	△	F	F	CO-NH-BSA
Coating antigens						
ORB-OVA	CH <sub>3</sub>	CH <sub>3</sub>	△	F	F	CO-NH-OVA
SPA-OVA	CH <sub>3</sub>	CH <sub>3</sub>	△	NH <sub>2</sub>	F	CO-NH-OVA
LOM-OVA	H	CH <sub>3</sub>	C <sub>2</sub> H <sub>5</sub>	H	F	CO-NH-OVA
Fluorescent tracers						
ORB-EDF	CH <sub>3</sub>	CH <sub>3</sub>	△	F	F	CO-NH-(CH <sub>2</sub> ) <sub>2</sub> -NH-FITC
ORB-BDF	CH <sub>3</sub>	CH <sub>3</sub>	△	F	F	CO-NH-(CH <sub>2</sub> ) <sub>4</sub> -NH-FITC
ORB-HDF	CH <sub>3</sub>	CH <sub>3</sub>	△	F	F	CO-NH-(CH <sub>2</sub> ) <sub>6</sub> -NH-FITC
LOM-EDF	CH <sub>3</sub>	CH <sub>3</sub>	C <sub>2</sub> H <sub>5</sub>	H	F	CO-NH-(CH <sub>2</sub> ) <sub>2</sub> -NH-FITC
LOM-BDF	CH <sub>3</sub>	CH <sub>3</sub>	C <sub>2</sub> H <sub>5</sub>	H	F	CO-NH-(CH <sub>2</sub> ) <sub>4</sub> -NH-FITC
LOM-HDF	CH <sub>3</sub>	CH <sub>3</sub>	C <sub>2</sub> H <sub>5</sub>	H	F	CO-NH-(CH <sub>2</sub> ) <sub>6</sub> -NH-FITC

510 △: cyclopropyl, ORB: Orbifloxacin, SPA: Sparfloxacin, LOM: Lomefloxacin, BSA: Bovine serum albumin, OVA:

511 ovalbumin, EDF: Fluorescein thiocarbamyl ethylenediamine, BDF: Fluorescein thiocarbamyl butanediamine,

512 HDF: Fluorescein thiocarbamyl hexylenediamine

1  
2  
3  
4  
513 Table 2. Determination of optimal concentrations for tracer LOM-BDF and antibody using  
6  
7  
8 514 checkerboard titration in FPIA.

Ab dilution	Parameter	LOM-BDF concentration (nM)			
		10	20	40	80
400	B/B <sub>0</sub>	0.967	0.900	0.843	0.748
	Z'	0.86	0.85	0.86	0.85
800	B/B <sub>0</sub>	0.904	0.809	0.696	0.780
	Z'	0.84	0.84	0.83	0.74
1600	B/B <sub>0</sub>	0.740	0.619	0.727	0.852
	Z'	0.82	0.81	0.67	0.53
3200	B/B <sub>0</sub>	0.588	0.670	0.784	0.921
	Z'	0.63	0.58	0.27	-0.33

9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30 515

B/B<sub>0</sub> was calculated at the ORB concentration of 20 ng mL<sup>-1</sup>.

516 Table 3. Cross-reactivity of several structurally related analogues in the ELISA and FPIA

Analyte	ELISA <sup>a</sup>			FPIA <sup>b</sup>		
	IC <sub>50</sub>	IC <sub>50</sub>	Cross-reactivity	IC <sub>50</sub>	IC <sub>50</sub>	Cross-reactivity
	(ng mL <sup>-1</sup> )	(nM)	(%)	(ng mL <sup>-1</sup> )	(nM)	(%)
ORB	5.94	15.0	100	22.4	56.7	100
SPA	10.5	25.5	58.9	27.8	70.8	80.1
LOM	106.7	275.1	5.45	197	507.9	11.2
Other QNs	>10 <sup>5</sup>	>10 <sup>5</sup>	<0.01	>10 <sup>5</sup>	>10 <sup>5</sup>	<0.01

517 <sup>a</sup> LOM-OVA was the coating antigen for the ELISA518 <sup>b</sup> LOM-BDF was the fluorescent tracer for the FPIA

519 Table 4. Recoveries of ORB from milk by FPIA and HPLC (n = 4)

ORB Added (ng mL <sup>-1</sup> )	FPIA			HPLC		
	Found (ng mL <sup>-1</sup> )	Recovery (%)	CV (%)	Found (ng mL <sup>-1</sup> )	Recovery (%)	CV (%)
10	11.2 ± 3.0	112	26.8	9.1 ± 1.2	91.0	13.2
20	16.6 ± 2.4	83.0	14.4	17.2 ± 1.5	86.0	8.7
40	29.7 ± 2.2	74.3	7.4	32.5 ± 2.5	81.3	7.7

520

521